Non-negligible/JJ
Occurrence/NN
of/IN
Errors/NNS
in/IN
Gender/NN
Description/NN
in/IN
Public/JJ
Data/NNS
Sets/NNS
./.
====================
Due/IN
to/TO
advances/NNS
in/IN
omics/NNS
technologies/NNS
,/,
numerous/JJ
genome-wide/NN
studies/NNS
on/IN
human/JJ
samples/NNS
have/VBP
been/VBN
published/VBN
,/,
and/CC
most/JJS
of/IN
the/DT
omics/NNS
data/NNS
with/IN
the/DT
associated/VBN
clinical/JJ
information/NN
are/VBP
available/JJ
in/IN
public/JJ
repositories/VBZ
,/,
such/JJ
as/IN
Gene/NN
Expression/NN
Omnibus/FW
and/CC
ArrayExpress/NN
./.
====================
While/IN
analyzing/VBG
several/JJ
public/JJ
datasets/NNS
,/,
we/PRP
observed/VBD
that/IN
errors/NNS
in/IN
gender/NN
information/NN
occur/VBP
quite/RB
often/RB
in/IN
public/JJ
datasets/NNS
./.
====================
When/WRB
we/PRP
analyzed/VBD
the/DT
gender/NN
description/NN
and/CC
the/DT
methylation/NN
patterns/NNS
of/IN
gender-specific/JJ
probes/NNS
(/(
glucose-6-phosphate/NN
dehydrogenase/NN
[/(
G6PD/NN
]/)
,/,
ephrin-B1/NN
[/(
EFNB1/NN
]/)
,/,
and/CC
testis/NN
specific/JJ
protein/NN
,/,
Y-linked/JJ
2/CD
[/(
TSPY2/NN
]/)
)/)
in/IN
5,611/CD
samples/NNS
produced/VBN
using/VBG
Infinium/NN
450K/NN
HumanMethylation/JJ
arrays/NNS
,/,
we/PRP
found/VBD
that/IN
19/CD
samples/NNS
from/IN
7/CD
datasets/NNS
were/VBD
erroneously/RB
described/VBN
./.
====================
We/PRP
also/RB
analyzed/VBD
1,819/CD
samples/NNS
produced/VBN
using/VBG
the/DT
Affymetrix/JJ
U133Plus2/NN
array/NN
using/VBG
several/JJ
gender-specific/JJ
genes/NNS
(/(
X/NN
(/(
inactive/JJ
)/)
-specific/JJ
transcript/NN
[/(
XIST/NN
]/)
,/,
eukaryotic/JJ
translation/NN
initiation/NN
factor/NN
1A/NN
,/,
Y-linked/JJ
[/(
EIF1AY/NN
]/)
,/,
and/CC
DEAD/NN
[/(
Asp-Glu-Ala-Asp/NN
]/)
box/NN
polypeptide/NN
3/CD
,/,
Y-linked/JJ
[/(
DDDX3Y/NN
]/)
)/)
and/CC
found/VBD
that/IN
40/CD
samples/NNS
from/IN
3/CD
datasets/NNS
were/VBD
erroneously/RB
described/VBN
./.
====================
We/PRP
suggest/VBP
that/IN
the/DT
users/NNS
of/IN
public/JJ
datasets/NNS
should/MD
not/RB
expect/VB
that/DT
the/DT
data/NNS
are/VBP
error-free/JJ
and/CC
,/,
whenever/RB
possible/JJ
,/,
that/DT
they/PRP
should/MD
check/VB
the/DT
consistency/NN
of/IN
the/DT
data/NNS
./.
====================
The/DT
completion/NN
of/IN
the/DT
human/JJ
genome/NN
project/VB
has/VBZ
accelerated/VBN
the/DT
development/NN
of/IN
many/JJ
omics/NNS
technologies/NNS
that/DT
have/VBP
been/VBN
used/VBN
extensively/RB
for/IN
the/DT
genomewide/NN
profiling/VBG
of/IN
human/JJ
samples/NNS
[/(
1/CD
]/)
./.
====================
Public/JJ
repositories/VBZ
,/,
such/JJ
as/IN
Gene/NN
Expression/NN
Omnibus/JJ
(/(
GEO/NN
)/)
and/CC
ArrayExpress/NN
,/,
now/RB
hold/RB
data/NNS
on/IN
hundreds/VBZ
of/IN
thousands/NNS
of/IN
samples/NNS
profiled/VBN
by/IN
diverse/JJ
technologies/NNS
[/(
23/CD
]/)
./.
====================
For/IN
many/JJ
of/IN
the/DT
samples/NNS
in/IN
the/DT
public/JJ
repositories/VBZ
,/,
various/JJ
kinds/NNS
of/IN
clinical/JJ
information/NN
are/VBP
also/RB
included/VBD
so/RB
that/IN
interested/JJ
researchers/NNS
can/MD
use/VB
them/PRP
for/IN
their/PRP$
own/JJ
research/NN
interests/NNS
./.
====================
While/IN
these/DT
public/JJ
data/NNS
have/VBP
enormous/JJ
potential/JJ
for/IN
research/NN
use/NN
,/,
it/PRP
is/VBZ
inevitable/JJ
that/DT
unknown/JJ
errors/NNS
may/MD
creep/VB
into/IN
public/JJ
datasets/NNS
without/IN
being/VBG
noticed/VBN
by/IN
depositors/NNS
./.
====================
For/IN
example/NN
,/,
Microsoft/NN
Excel/JJ
is/VBZ
notorious/JJ
for/IN
its/PRP$
automatic/JJ
conversion/NN
function/NN
,/,
which/WDT
erroneously/RB
changes/NNS
tens/NNS
of/IN
human/JJ
gene/NN
symbols/NNS
[/(
4/CD
]/)
./.
====================
But/CC
,/,
the/DT
errors/NNS
are/VBP
not/RB
limited/JJ
to/TO
gene/NN
symbols/NNS
and/CC
may/MD
occur/VB
in/IN
the/DT
clinical/JJ
information/NN
,/,
as/IN
well/RB
./.
====================
Age/NN
and/CC
gender/NN
are/VBP
some/DT
of/IN
the/DT
most/JJS
basic/JJ
clinical/JJ
information/NN
associated/VBN
with/IN
human/JJ
samples/NNS
and/CC
are/VBP
most/RBS
unlikely/RB
to/TO
be/VB
erroneous/JJ
during/IN
data/NNS
acquisition/NN
./.
====================
While/IN
they/PRP
are/VBP
basic/JJ
clinical/JJ
information/NN
,/,
the/DT
importance/NN
of/IN
age/NN
and/CC
gender/NN
in/IN
human/JJ
biology/NN
is/VBZ
not/RB
trivial/JJ
./.
====================
There/EX
is/VBZ
strong/JJ
evidence/NN
that/IN
men/NNS
and/CC
women/NNS
differ/VBP
in/IN
terms/NNS
of/IN
development/NN
and/CC
severity/NN
of/IN
many/JJ
common/JJ
diseases/NNS
,/,
including/VBG
cardiovascular/JJ
diseases/NNS
,/,
autoimmune/JJ
diseases/NNS
,/,
and/CC
asthma/NN
[/(
5/CD
]/)
./.
====================
Recent/JJ
clinical/JJ
studies/NNS
have/VBP
revealed/VBN
an/DT
association/NN
between/IN
several/JJ
genetic/JJ
diseases/NNS
and/CC
gender-specific/JJ
genetic/JJ
patterns/NNS
[/(
67/CD
]/)
./.
====================
While/IN
analyzing/VBG
public/JJ
datasets/NNS
produced/VBN
using/VBG
Infinium/NN
450K/NN
HumanMethylation/JJ
arrays/NNS
(/(
Illumina/NN
Inc./NNP
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
Affymetrix/JJ
Human/JJ
Genome/NN
U133Plus/NNP
2.0/CD
arrays/NNS
(/(
Affymetrix/JJ
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
we/PRP
found/VBD
many/JJ
samples/NNS
that/IN
were/VBD
discordant/JJ
between/IN
clinical/JJ
gender/NN
information/NN
and/CC
the/DT
patterns/NNS
of/IN
gender-specific/JJ
markers/NNS
./.
====================
Importantly/RB
,/,
the/DT
errors/NNS
were/VBD
not/RB
limited/JJ
to/TO
a/DT
few/JJ
datasets/NNS
but/CC
were/VBD
prevalent/JJ
in/IN
many/JJ
datasets/NNS
produced/VBN
by/IN
many/JJ
different/JJ
laboratories/NNS
./.
====================
We/PRP
advise/VBP
that/DT
the/DT
users/NNS
of/IN
public/JJ
datasets/NNS
should/MD
not/RB
expect/VB
that/DT
these/DT
data/NNS
are/VBP
error-free/JJ
and/CC
,/,
whenever/RB
possible/JJ
,/,
that/DT
they/PRP
check/VBP
the/DT
consistency/NN
of/IN
data/NNS
./.
====================
Data/NNS
collection/NN
and/CC
processing/NN
====================
Infinium/NN
450K/NN
HumanMethylation/NN
array/NN
====================
More/RBR
than/IN
5,600/CD
samples/NNS
from/IN
11/CD
datasets/NNS
were/VBD
collected/VBN
from/IN
GEO/NN
[/(
2/CD
]/)
./.
====================
Before/IN
data/NNS
integration/NN
,/,
we/PRP
calculated/VBD
the/DT
average/NN
beta/NN
value/NN
for/IN
measuring/VBG
methylation/NN
levels/NNS
at/IN
each/DT
CpG/NN
site/NN
,/,
ranging/VBG
from/IN
0/CD
(/(
least/JJS
methylated/VBN
)/)
to/TO
1/CD
(/(
most/JJS
methylated/VBN
)/)
./.
====================
The/DT
individual/JJ
beta/NN
value/NN
was/VBD
dropped/VBN
if/IN
the/DT
detection/NN
p-value/NN
was/VBD
over/IN
0.05/CD
./.
====================
For/IN
all/DT
datasets/NNS
,/,
raw/RB
signal/NN
intensity/NN
files/NNS
were/VBD
collected/VBN
,/,
and/CC
from/IN
them/PRP
,/,
methylation/NN
level/NN
was/VBD
calculated/VBN
as/IN
β/RB
=/JJ
(/(
max/NN
(/(
Cy5/NN
,/,
0/CD
)/)
)/)
//:
(/(
|Cy3|/NNP
+/JJ
|Cy5|/NNP
+/JJ
100/CD
)/)
./.
====================
A/DT
constant/JJ
of/IN
100/CD
was/VBD
added/VBN
to/TO
the/DT
denominator/NN
to/TO
regularize/VB
β/RB
values/NNS
when/WRB
both/CC
unmethylated/JJ
and/CC
methylated/VBN
intensities/NNS
were/VBD
small/JJ
./.
====================
Affymetrix/JJ
U133Plus2/NN
array/NN
====================
A/DT
total/JJ
of/IN
1,819/CD
samples/NNS
from/IN
4/CD
datasets/NNS
for/IN
gene/NN
expression/NN
experiments/NNS
using/VBG
the/DT
Affymetrix/JJ
U133Plus2/NN
array/NN
were/VBD
obtained/VBN
from/IN
GEO/NN
[/(
2/CD
]/)
./.
====================
For/IN
all/DT
datasets/NNS
,/,
CEL/NN
files/NNS
were/VBD
collected/VBN
and/CC
normalized/VBD
by/IN
Robust/NNP
Multiarray/JJ
Average/NN
method/NN
[/(
8/CD
]/)
./.
====================
Selection/NN
of/IN
gender-specific/JJ
DNA/NN
methylation/NN
and/CC
gene/NN
expression/NN
markers/NNS
====================
The/DT
gender-specific/JJ
DNA/NN
methylation/NN
markers/NNS
of/IN
the/DT
X/NN
chromosome/NN
were/VBD
selected/VBN
from/IN
reported/VBN
X-linked/JJ
housekeeping/JJ
genes/NNS
[/(
9/CD
]/)
./.
====================
The/DT
gender-specific/JJ
DNA/NN
methylation/NN
markers/NNS
of/IN
the/DT
Y/NN
chromosome/NN
were/VBD
estimated/VBN
using/VBG
differentially/RB
methylated/VBN
CpG/NN
sites/NNS
in/IN
Y/NN
chromosomes/NNS
between/IN
males/NNS
and/CC
females/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Gender-specific/JJ
markers/NNS
were/VBD
selected/VBN
based/VBN
on/IN
their/PRP$
beta/NN
value/NN
distribution/NN
in/IN
both/CC
males/NNS
and/CC
females/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
two/CD
markers/NNS
(/(
cg24139739/CD
and/CC
cg02869694/NN
)/)
were/VBD
selected/VBN
as/IN
X/NN
chromosome/NN
markers/NNS
,/,
and/CC
two/CD
markers/NNS
(/(
cg07851521/NN
and/CC
cg10835413/NN
)/)
were/VBD
selected/VBN
as/IN
Y/NN
chromosome/NN
markers/NNS
./.
====================
The/DT
cutoff/JJ
values/NNS
for/IN
each/DT
marker/NN
were/VBD
cg24139739/CD
</JJR
0.25/CD
,/,
cg02869694/NN
</JJR
0.4/CD
,/,
cg07851521/NN
>/JJR
0.5/CD
,/,
and/CC
cg10835413/NN
>/JJR
0.45/CD
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
gender-specific/JJ
gene/NN
expression/NN
markers/NNS
were/VBD
selected/VBN
from/IN
reported/VBN
gender-specific/JJ
gene/NN
expression/NN
patterns/NNS
in/IN
human/JJ
blood/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
in/IN
a/DT
similar/JJ
way/NN
[/(
10/CD
]/)
./.
====================
Two/CD
markers/NNS
(/(
214218_s_at/CD
and/CC
224588_at/JJ
)/)
were/VBD
selected/VBN
as/IN
X/NN
chromosome/NN
markers/NNS
,/,
and/CC
two/CD
markers/NNS
(/(
204409_s_at/JJ
and/CC
205000_at/JJ
)/)
were/VBD
selected/VBN
as/IN
Y/NN
chromosome/NN
markers/NNS
./.
====================
The/DT
cutoff/JJ
values/NNS
for/IN
each/DT
marker/NN
were/VBD
214218_s_at/RB
</JJR
4.5/CD
,/,
224588_at/JJ
</JJR
7.5/CD
,/,
204409_s_at/JJ
>/JJR
5/CD
,/,
and/CC
205000_at/JJ
>/JJR
5/CD
./.
====================
Data/NNS
analysis/NN
====================
Python/NN
version/NN
2.7.6/CD
and/CC
the/DT
Pandas/NN
python/NN
library/NN
version/NN
0.15.2/CD
were/VBD
used/VBN
for/IN
most/JJS
data/NNS
analyses/NNS
./.
====================
R/NN
version/NN
3.1.0/CD
and/CC
ggplot2/NN
version/NN
1.0.0/CD
were/VBD
used/VBN
for/IN
image/NN
production/NN
./.
====================
Collection/NN
of/IN
DNA/NN
methylation/NN
array/NN
data/NNS
of/IN
human/JJ
whole/JJ
blood/NN
with/IN
age/NN
and/CC
gender/NN
information/NN
====================
We/PRP
obtained/VBD
DNA/NN
methylation/NN
microarray/NN
data/NNS
from/IN
the/DT
NCBI/NN
GEO/NN
database/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
We/PRP
collected/VBD
datasets/NNS
of/IN
normal/JJ
human/JJ
blood/NN
samples/NNS
in/IN
which/WDT
both/CC
age/NN
and/CC
gender/NN
data/NNS
were/VBD
available/JJ
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
collected/VBD
a/DT
total/JJ
of/IN
4,862/CD
samples/NNS
for/IN
Infinium/NN
450K/NN
HumanMethylation/NN
array/NN
data/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Determination/NN
of/IN
gender/NN
by/IN
gender-specific/JJ
markers/NNS
====================
The/DT
CpG/NN
sites/NNS
of/IN
X/NN
chromosomes/NNS
in/IN
females/NNS
are/VBP
hypermethylated/VBN
for/IN
dosage/JJ
compensation/NN
of/IN
female/JJ
X/NN
chromosomes/NNS
[/(
11/CD
]/)
./.
====================
By/IN
analyzing/VBG
female-specific/JJ
hypermethylated/JJ
genes/NNS
in/IN
the/DT
X/NN
chromosome/NN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
,/,
we/PRP
identified/VBD
19/CD
samples/NNS
(/(
0.39/CD
%/NN
)/)
in/IN
which/WDT
the/DT
methylation/NN
patterns/NNS
of/IN
gender-specific/JJ
CpG/NN
markers/NNS
did/VBD
not/RB
match/VB
the/DT
given/VBN
gender/NN
information/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
When/WRB
we/PRP
analyzed/VBD
those/DT
samples/NNS
with/IN
male-specific/JJ
hypermethylated/JJ
genes/NNS
in/IN
the/DT
Y/NN
chromosome/NN
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
,/,
we/PRP
again/RB
observed/VBN
the/DT
opposite/JJ
methylation/NN
patterns/NNS
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
Importantly/RB
,/,
the/DT
discordant/JJ
patterns/NNS
were/VBD
observed/VBN
in/IN
eight/CD
of/IN
11/CD
datasets/NNS
from/IN
different/JJ
depositors/NNS
,/,
suggesting/VBG
that/IN
the/DT
errors/NNS
were/VBD
not/RB
limited/JJ
to/TO
one/CD
laboratory/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Interestingly/RB
,/,
we/PRP
found/VBD
both/CC
types/NNS
of/IN
discordant/JJ
errors/NNS
between/IN
DNA/NN
methylation/NN
patterns/NNS
and/CC
given/VBN
gender/NN
information/NN
./.
====================
That/DT
is/VBZ
,/,
for/IN
some/DT
samples/NNS
,/,
DNA/NN
methylation/NN
patterns/NNS
were/VBD
found/VBN
to/TO
be/VB
female-specific/JJ
while/IN
they/PRP
were/VBD
designated/VBN
as/IN
males/NNS
(/(
designated/VBN
here/RB
as/IN
discordant-male/JJ
)/)
,/,
and/CC
for/IN
the/DT
other/JJ
samples/NNS
,/,
DNA/NN
methylation/NN
patterns/NNS
were/VBD
male-specific/JJ
while/IN
they/PRP
were/VBD
designated/VBN
as/IN
female/JJ
(/(
designated/VBN
here/RB
as/IN
discordant-female/JJ
)/)
./.
====================
Analysis/NN
of/IN
markers/NNS
of/IN
chromosome/NN
abnormality/NN
syndromes/NNS
====================
We/PRP
next/RB
analyzed/VBD
whether/IN
the/DT
observed/VBN
discrepancy/NN
between/IN
methylation/NN
patterns/NNS
of/IN
gender-specific/JJ
genes/NNS
and/CC
the/DT
given/VBN
clinical/JJ
information/NN
could/MD
be/VB
explained/VBN
by/IN
rare/JJ
sex/NN
chromosome/NN
abnormality/NN
syndromes/NNS
,/,
such/JJ
as/IN
Turner/NN
and/CC
Klinefelter/NN
syndromes/NNS
./.
====================
While/IN
a/DT
normal/JJ
male/JJ
inherits/VBZ
an/DT
X/NN
chromosome/NN
and/CC
a/DT
Y/NN
chromosome/NN
and/CC
a/DT
normal/JJ
female/JJ
inherits/VBZ
two/CD
X/NN
chromosomes/NNS
,/,
several/JJ
abnormalities/NNS
in/IN
the/DT
number/NN
of/IN
sex/NN
chromosomes/NNS
occur/VBP
gender-specifically/RB
./.
====================
For/IN
females/NNS
,/,
abnormalities/NNS
are/VBP
a/DT
result/NN
of/IN
variations/NNS
in/IN
the/DT
number/NN
of/IN
X/NN
chromosomes/NNS
./.
====================
For/IN
males/NNS
,/,
abnormalities/NNS
are/VBP
due/JJ
to/TO
irregular/JJ
numbers/NNS
of/IN
the/DT
X/NN
or/CC
Y/NN
chromosome/NN
or/CC
both/CC
./.
====================
The/DT
most/JJS
frequent/JJ
sex/NN
chromosome/NN
abnormalities/NNS
in/IN
females/NNS
are/VBP
Turner/NN
(/(
one/CD
X/NN
;/:
1:2,000/CD
)/)
and/CC
triple/JJ
X/NN
(/(
XXX/NN
;/:
1:1,000/CD
)/)
,/,
while/IN
those/DT
in/IN
males/NNS
are/VBP
Klinefelter/JJ
(/(
XXY/NN
;/:
1:500/CD
)/)
and/CC
XYY/NN
(/(
1:1,000/CD
)/)
syndromes/NNS
[/(
12131415/CD
]/)
./.
====================
For/IN
comparison/NN
,/,
we/PRP
collected/VBD
Infinium/NN
450K/NN
Human-Methylation/NN
array/NN
data/NNS
of/IN
one/CD
Turner/NN
syndrome/NN
patient/NN
and/CC
five/CD
Klinefelter/NN
syndrome/NN
patients/NNS
./.
====================
The/DT
characteristic/JJ
methylation/NN
pattern/NN
of/IN
Turner/NN
syndrome/NN
(/(
one/CD
X/NN
)/)
is/VBZ
the/DT
hypomethylation/NN
of/IN
both/DT
X-/JJ
and/CC
Y-specific/JJ
markers/NNS
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
However/RB
,/,
we/PRP
found/VBD
that/IN
most/JJS
discordant-female/JJ
samples/NNS
in/IN
our/PRP$
dataset/NN
showed/VBD
hypermethylation/NN
patterns/NNS
in/IN
Y-specific/JJ
markers/NNS
,/,
suggesting/VBG
that/IN
they/PRP
had/VBD
XY/NN
chromosomes/NNS
(/(
a/DT
normal/JJ
male/JJ
)/)
but/CC
not/RB
X/NN
(/(
Turner/NN
syndrome/NN
)/)
chromosome/NN
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
Only/RB
one/CD
discordant-female/JJ
sample/NN
(/(
green/CD
circle/NN
in/IN
Fig/NN
./.
====================
2A/NN
)/)
showed/VBD
a/DT
pattern/NN
similar/JJ
to/TO
Turner/NN
syndrome/NN
./.
====================
For/IN
Klinefelter/NN
syndrome/NN
(/(
XXY/NN
)/)
,/,
the/DT
expected/VBN
methylation/NN
patterns/NNS
are/VBP
the/DT
hypermethylation/NN
of/IN
both/DT
male-/NN
and/CC
female-specific/JJ
markers/NNS
./.
====================
We/PRP
observed/VBD
one/CD
discordant-male/JJ
sample/NN
in/IN
which/WDT
both/CC
male-/NN
and/CC
female-specific/JJ
markers/NNS
were/VBD
hypermethylated/VBN
(/(
red/JJ
circles/NNS
in/IN
Figs/NNS
./.
====================
2B/NN
and/CC
3A/NN
)/)
./.
====================
However/RB
,/,
a/DT
close/JJ
examination/NN
of/IN
three/CD
Klinefelter/NN
syndrome-specific/JJ
markers/NNS
revealed/VBD
that/IN
the/DT
one/CD
discordant-male/JJ
sample/NN
did/VBD
not/RB
show/VB
the/DT
patterns/NNS
of/IN
a/DT
Klinefelter/NN
syndrome/NN
patient/NN
(/(
Fig/NN
./.
====================
3B/NN
,/,
Supplementary/JJ
Fig/NN
./.
====================
4/CD
)/)
[/(
16/CD
]/)
./.
====================
In/IN
conclusion/NN
,/,
only/RB
one/CD
sample/NN
showed/VBD
a/DT
methylation/NN
pattern/NN
associated/VBN
with/IN
sex/NN
chromosome/NN
abnormalities/NNS
./.
====================
Significant/JJ
difference/NN
between/IN
clinical/JJ
age/NN
information/NN
and/CC
predicted/VBN
age/NN
using/VBG
a/DT
DNA/NN
methylation/NN
age/NN
calculator/NN
====================
Recently/RB
,/,
several/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
DNA/NN
methylation/NN
markers/NNS
can/MD
be/VB
used/VBN
to/TO
estimate/VB
the/DT
age/NN
of/IN
an/DT
individual/JJ
to/TO
within/IN
5/CD
y/NN
[/(
17/CD
]/)
./.
====================
Because/IN
the/DT
datasets/NNS
we/PRP
analyzed/VBD
had/VBD
age/NN
information/NN
,/,
as/IN
well/RB
,/,
we/PRP
tested/VBD
whether/IN
the/DT
given/VBN
age/NN
information/NN
deviated/VBN
much/RB
from/IN
the/DT
estimated/VBN
age/NN
from/IN
age-specific/JJ
DNA/NN
methylation/NN
markers/NNS
./.
====================
The/DT
age/NN
prediction/NN
was/VBD
performed/VBN
by/IN
using/VBG
the/DT
DNA/NN
methylation/NN
age/NN
calculator/NN
,/,
a/DT
web-based/JJ
tool/NN
that/DT
provides/VBZ
a/DT
predicted/VBN
age/NN
based/VBN
on/IN
the/DT
methylation/NN
values/NNS
of/IN
DNA/NN
methylation/NN
markers/NNS
of/IN
Illumina/NN
's/POS
Infinium/NN
platform/NN
[/(
18/CD
]/)
./.
====================
When/WRB
we/PRP
compared/VBD
the/DT
absolute/JJ
age/NN
deviation/NN
between/IN
concordant/JJ
and/CC
discordant/JJ
samples/NNS
,/,
we/PRP
found/VBD
much/RB
larger/JJR
deviations/NNS
in/IN
age/NN
prediction/NN
among/IN
discordant/JJ
samples/NNS
compared/VBN
with/IN
concordant/JJ
samples/NNS
(/(
Table/JJ
1/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
5/CD
)/)
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
the/DT
discordant/JJ
samples/NNS
are/VBP
highly/RB
likely/RB
to/TO
have/VB
errors/NNS
both/CC
in/FW
age/NN
and/CC
gender/NN
information/NN
,/,
a/DT
scenario/NN
that/DT
occurs/VBZ
when/WRB
two/CD
samples/NNS
are/VBP
mislabeled/VBN
as/IN
each/DT
other/JJ
./.
====================
Identification/NN
of/IN
gender-discordant/JJ
samples/NNS
from/IN
the/DT
analysis/NN
of/IN
gender-specific/JJ
gene/NN
expression/NN
====================
To/TO
see/VB
if/IN
the/DT
same/JJ
problem/NN
occurs/VBZ
in/IN
other/JJ
types/NNS
of/IN
data/NNS
(/(
e.g./FW
,/,
gene/NN
expression/NN
)/)
,/,
we/PRP
collected/VBD
gene/NN
expression/NN
microarray/NN
data/NNS
from/IN
the/DT
NCBI/NN
GEO/NN
database/NN
using/VBG
a/DT
similar/JJ
strategy/NN
for/IN
methylation/NN
microarray/NN
data/NNS
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
By/IN
applying/VBG
the/DT
same/JJ
criteria/NNS
as/IN
with/IN
the/DT
DNA/NN
methylation/NN
data/NNS
,/,
we/PRP
collected/VBD
a/DT
total/JJ
of/IN
1,683/CD
samples/NNS
from/IN
4/CD
datasets/NNS
produced/VBN
using/VBG
the/DT
Affymetrix/JJ
U133Plus2/NN
array/NN
platform/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
We/PRP
analyzed/VBD
the/DT
1,683/NN
samples/NNS
using/VBG
several/JJ
gender-specific/JJ
genes/NNS
(/(
X/NN
(/(
inactive/JJ
)/)
-specific/JJ
transcript/NN
[/(
XIST/NN
]/)
,/,
eukaryotic/JJ
translation/NN
initiation/NN
factor/NN
1A/NN
,/,
Y-linked/JJ
[/(
EIF1AY/NN
]/)
,/,
and/CC
DEAD/NN
[/(
Asp-Glu-Ala-Asp/NN
]/)
box/NN
polypeptide/NN
3/CD
,/,
Y-linked/JJ
[/(
DDDX3Y/NN
]/)
)/)
[/(
10/CD
]/)
and/CC
found/VBD
that/IN
40/CD
samples/NNS
(/(
2.3/CD
%/NN
)/)
from/IN
3/CD
datasets/NNS
were/VBD
erroneously/RB
described/VBN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
In/IN
the/DT
case/NN
of/IN
Y/NN
chromosome/NN
markers/NNS
,/,
some/DT
discordant/JJ
male/JJ
samples/NNS
showed/VBD
overlapping/VBG
distribution/NN
of/IN
methylation/NN
levels/NNS
compared/VBD
with/IN
normal/JJ
male/JJ
samples/NNS
./.
====================
Those/DT
samples/NNS
needed/VBN
to/TO
be/VB
compared/VBN
samples/NNS
with/IN
male/JJ
sex/NN
abnormality/NN
syndromes/NNS
(/(
e.g./FW
,/,
Klinefelter/NN
syndrome/NN
)/)
,/,
but/CC
unfortunately/RB
,/,
we/PRP
could/MD
not/RB
find/VB
datasets/NNS
with/IN
male/JJ
sex/NN
abnormality/NN
syndromes/NNS
produced/VBN
using/VBG
the/DT
same/JJ
platform/NN
./.
====================
However/RB
,/,
as/IN
these/DT
samples/NNS
showed/VBD
the/DT
opposite/JJ
pattern/NN
in/IN
X/NN
chromosome/NN
markers/NNS
,/,
we/PRP
considered/VBD
them/PRP
to/TO
be/VB
putative/JJ
discordant/JJ
samples/NNS
./.
====================
But/CC
,/,
further/RBR
validation/NN
will/MD
be/VB
needed/VBN
to/TO
confirm/VB
these/DT
samples/NNS
./.
====================
Unlike/IN
the/DT
previous/JJ
methylation/NN
data/NNS
,/,
some/DT
of/IN
the/DT
collected/JJ
gene/NN
expression/NN
datasets/NNS
contained/VBD
technical/JJ
replicates/VBZ
of/IN
the/DT
same/JJ
samples/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
Surprisingly/RB
,/,
discordant/JJ
gender-specific/JJ
expression/NN
patterns/NNS
were/VBD
even/RB
observed/VBN
from/IN
some/DT
of/IN
the/DT
technically/RB
replicated/VBD
samples/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
6/CD
)/)
./.
====================
Recently/RB
,/,
genomewide/NN
omics/NNS
data/NNS
have/VBP
accumulated/VBN
very/RB
fast/JJ
due/JJ
to/TO
advances/NNS
in/IN
omics/NNS
technologies/NNS
(/(
e.g./FW
,/,
Illumina/NN
's/POS
Infinium/NN
methylation/NN
assay/NN
and/CC
next-generation/NN
sequencing/NN
)/)
./.
====================
Now/RB
,/,
researchers/NNS
can/MD
exploit/VB
public/JJ
data/NNS
repositories/VBZ
(/(
e.g./FW
,/,
ArrayExpress/RB
[/(
3/CD
]/)
and/CC
GEO/NN
[/(
2/CD
]/)
)/)
that/WDT
store/RB
data/NNS
of/IN
hundreds/VBZ
of/IN
thousands/NNS
of/IN
samples/NNS
with/IN
both/DT
genomewide/JJ
profiling/VBG
data/NNS
and/CC
associated/VBN
clinical/JJ
information/NN
./.
====================
However/RB
,/,
as/IN
we/PRP
have/VBP
shown/VBN
here/RB
,/,
datasets/NNS
are/VBP
not/RB
error-free/JJ
,/,
and/CC
any/DT
type/NN
of/IN
error/JJ
can/MD
occur/VB
in/IN
public/JJ
datasets/NNS
./.
====================
Indeed/RB
,/,
one/CD
paper/NN
reported/VBD
that/IN
the/DT
aggregate/NN
mislabeled/JJ
blood/NN
sample/NN
rate/NN
was/VBD
1.12/CD
%/NN
at/IN
various/JJ
US/NN
institutions/NNS
in/IN
2013/CD
[/(
19/CD
]/)
./.
====================
Possibly/RB
,/,
various/JJ
kinds/NNS
of/IN
errors/NNS
(/(
e.g./FW
,/,
mislabeling/VBG
of/IN
tubes/NNS
,/,
mixing/JJ
of/IN
samples/NNS
)/)
may/MD
occur/VB
from/IN
sample/JJ
preparation/NN
to/TO
various/JJ
steps/NNS
of/IN
the/DT
experimental/JJ
procedures/NNS
./.
====================
When/WRB
we/PRP
began/VBD
the/DT
analysis/NN
of/IN
Infinium/NN
450K/NN
Human-Methylation/NN
array/NN
data/NNS
,/,
we/PRP
did/VBD
not/RB
expect/VB
errors/NNS
in/IN
gender/NN
description/NN
to/TO
occur/VB
so/RB
often/RB
in/IN
several/JJ
datasets/NNS
./.
====================
We/PRP
thus/RB
analyzed/VBD
if/IN
those/DT
erroneous/JJ
samples/NNS
showed/VBD
the/DT
methylation/NN
patterns/NNS
of/IN
gender-specific/JJ
chromosome/NN
abnormality/NN
syndromes/NNS
(/(
e.g./FW
,/,
Turner/NN
and/CC
Klinefelter/NN
syndromes/NNS
)/)
but/CC
found/VBD
that/IN
most/JJS
of/IN
the/DT
erroneous/JJ
samples/NNS
did/VBD
not/RB
./.
====================
Thus/RB
,/,
we/PRP
concluded/VBD
that/IN
most/JJS
discordant/JJ
samples/NNS
were/VBD
real/JJ
human/JJ
errors/NNS
./.
====================
This/DT
finding/NN
led/VBD
us/PRP
to/TO
analyze/VB
expression/NN
datasets/NNS
of/IN
Affymetrix/JJ
U133Plus2/NN
array/NN
data/NNS
,/,
as/IN
well/RB
,/,
and/CC
again/RB
,/,
we/PRP
found/VBD
that/IN
errors/NNS
were/VBD
not/RB
rare/JJ
as/IN
well/RB
./.
====================
Fortunately/RB
,/,
for/IN
transcriptomic/JJ
and/CC
epigenomic/JJ
datasets/NNS
,/,
gender-specific/JJ
markers/NNS
(/(
Supplementary/JJ
Tables/NNS
1/CD
,/,
2/CD
,/,
3/CD
,/,
4/CD
)/)
are/VBP
well/RB
known/VBN
,/,
so/RB
that/IN
researchers/NNS
can/MD
check/VB
whether/IN
the/DT
given/VBN
gender/NN
information/NN
is/VBZ
concordant/JJ
with/IN
the/DT
expected/VBN
patterns/NNS
of/IN
gender-specific/JJ
markers/NNS
./.
====================
For/IN
DNA/NN
methylation/NN
,/,
a/DT
user-friendly/RB
website/JJ
(/(
https/NNS
:/:
//dnamage.genetics.ucla.edu//JJ
)/)
[/(
18/CD
]/)
is/VBZ
also/RB
available/JJ
for/IN
researchers/NNS
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
suggest/VBP
that/IN
users/VBZ
of/IN
public/JJ
data/NNS
should/MD
not/RB
expect/VB
that/DT
the/DT
data/NNS
are/VBP
error-free/JJ
,/,
and/CC
whenever/IN
possible/JJ
,/,
they/PRP
should/MD
check/VB
them/PRP
carefully/RB
before/IN
use/NN
./.
====================
Work/NN
flow/NN
of/IN
the/DT
Infinium/NN
450K/NN
HumanMethylation/NN
array/NN
data/NNS
analysis/NN
./.
====================
Methylation/NN
pattern/NN
of/IN
gender-specific/JJ
markers/NNS
./.
====================
X/NN
(/(
A/NN
)/)
and/CC
Y/NN
(/(
B/NN
)/)
chromosome/NN
markers/NNS
./.
====================
The/DT
red/JJ
circles/NNS
indicate/VBP
the/DT
discordant/JJ
male/JJ
sample/NN
showing/VBG
overlapping/VBG
distribution/NN
of/IN
levels/NNS
for/IN
normal/JJ
male/JJ
samples/NNS
./.
====================
M/NN
,/,
male/JJ
;/:
F/NN
,/,
female/JJ
;/:
M_dis/NNP
,/,
male/JJ
samples/NNS
showing/VBG
methylation/NN
patterns/NNS
of/IN
females/NNS
;/:
F_dis/NNP
,/,
female/JJ
samples/NNS
showing/VBG
methylation/NN
patterns/NNS
of/IN
males/NNS
./.
====================
Comparison/NN
of/IN
methylation/NN
status/NN
between/IN
normal/JJ
and/CC
sex/NN
chromosome/NN
abnormalities/NNS
./.
====================
(/(
A/NN
)/)
Scatterplot/NN
of/IN
methylation/NN
status/NN
of/IN
gender-specific/JJ
methylation/NN
markers/NNS
on/IN
X/NN
and/CC
Y/NN
chromosomes/NNS
./.
====================
The/DT
red/JJ
circle/NN
indicates/VBZ
the/DT
sample/NN
with/IN
suspected/JJ
Klinefelter/NN
syndrome/NN
./.
====================
The/DT
green/VBN
circle/NN
indicates/VBZ
the/DT
sample/NN
with/IN
suspected/JJ
Turner/NN
syndrome/NN
./.
====================
(/(
B/NN
)/)
Box/NN
plot/NN
of/IN
Klinefelter/NN
syndrome-specific/JJ
methylation/NN
markers/NNS
of/IN
normal/JJ
males/NNS
,/,
normal/JJ
females/NNS
,/,
a/DT
sample/JJ
with/IN
suspected/JJ
Klinefelter/NN
syndrome/NN
,/,
and/CC
Klinefelter/NN
syndrome/NN
samples/NNS
./.
====================
M/NN
,/,
male/JJ
;/:
F/NN
,/,
female/JJ
;/:
M_dis/NNP
,/,
male/JJ
samples/NNS
showing/VBG
methylation/NN
patterns/NNS
of/IN
females/NNS
;/:
F_dis/NNP
,/,
female/JJ
samples/NNS
showing/VBG
methylation/NN
patterns/NNS
of/IN
males/NNS
;/:
T/NN
,/,
Turner/NN
syndrome/NN
sample/JJ
;/:
KS/NNS
,/,
Klinefelter/NN
syndrome/NN
sample/JJ
;/:
KS_sus/NNP
,/,
Klinefelter/NN
syndrome-suspected/JJ
sample/JJ
./.
====================
Work/NN
flow/NN
of/IN
the/DT
Affymetrix/JJ
Human/JJ
Genome/NN
U133Plus/NN
2.0/CD
array/NN
analysis/NN
./.
====================
Patterns/NN
of/IN
gender-specific/JJ
gene/NN
expression/NN
of/IN
X-/JJ
and/CC
Y-specific/JJ
genes/NNS
./.
====================
X/NN
(/(
A/NN
)/)
and/CC
Y/NN
(/(
B/NN
)/)
chromosome/NN
markers/NNS
./.
====================
The/DT
red/JJ
circles/NNS
indicate/VBP
the/DT
discordant/JJ
male/JJ
samples/NNS
showing/VBG
overlapping/VBG
distribution/NN
of/IN
levels/NNS
for/IN
normal/JJ
male/JJ
samples/NNS
./.
====================
M/NN
,/,
male/JJ
;/:
F/NN
,/,
female/JJ
;/:
M_dis/NNP
,/,
male/JJ
samples/NNS
showing/VBG
methylation/NN
patterns/NNS
of/IN
females/NNS
;/:
F_dis/NNP
,/,
female/JJ
samples/NNS
showing/VBG
methylation/NN
patterns/NNS
of/IN
males/NNS
./.
====================
Collected/JJ
Infinium/NN
450K/NN
HumanMethylation/NN
array/NN
samples/NNS
and/CC
information/NN
on/IN
discordant/JJ
samples/NNS
====================
Collected/JJ
Affymetrix/JJ
U133Plus2/NN
array/NN
datasets/NNS
and/CC
information/NN
on/IN
discordant/JJ
samples/NNS
====================
